Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer
Status:
Completed
Trial end date:
2018-10-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine safety and feasibility of adjuvant hyperthermic
intraperitoneal chemotherapy (HIPEC) with mitomycin and cisplatin in patients with locally
advanced gastric cancer undergoing standard surgical resection. Patients will be treated with
HIPEC using a single dose of mitomycin 15mg/m2 and cisplatin 50mg/m2 at 41-42 C for 90
minutes, during the definitive surgical resection for gastric cancer. HIPEC will be performed
after resection but before anastomosis.